EVERGREEN Study Evaluates Everolimus After Progression in Advanced ER-Positive, HER2-Negative Breast Cancer
For patients with estrogen receptor-positive, HER2-negative advanced breast cancer, the moment a tumor progresses on a CDK4/6 inhibitor can feel ...

